Related Experiment Video
Updated: Aug 9, 2025
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the
Jürgen Wolf1, Edward B Garon2, Harry J M Groen3
1Department of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany.
Introduction:
Capmatinib, a MET inhibitor, showed substantial antitumour activity with manageable side effects in patients with MET exon 14 (METex14)-mutated advanced non-small cell lung cancer (aNSCLC) in the GEOMETRY mono-1 study. We report patient-reported outcomes (PROs) from this study.
Methods:
Enrolled treatment-naïve (1L) or pre-treated (2L+) patients with aNSCLC with a METex14-skipping mutation received 400 mg capmatinib twice daily during 21-day treatment cycles. PROs were collected at baseline and every six weeks thereafter using EORTC QLQ-C30 global health status/quality of life (GHS/QoL), QLQ-LC13 symptoms, and EQ-5D-5L visual analogue scale (VAS) questionnaires.
Results:
As of 6 January 2020, 27/28 1L and 65/69 2L+ patients had completed PROs at baseline; compliance rates remained >70%. Cough improved early, with meaningful improvements (≥10-point change from baseline) observed throughout cycles (mean change from baseline [SD] by week 7: 1L -13.0 [39.9], 2L+ -8.2 [28.4]; week 43: 1L -28.2 [26.7], 2L+ -10.5 [27.3]). QoL, assessed by GHS/QoL and VAS, improved by week 7 in 1L and 2L+ patients, with improvements generally sustained over time. Median time to definitive deterioration (TTDD) in GHS/QoL was 16.6 months (95% CI: 9.7, not estimable [NE]) in 1L and 12.4 months (95% CI: 4.2, 19.4) in 2L+ patients. Median TTDD for dyspnoea was 19.4 months (95% CI: 12.4, NE) and 22.1 months (95% CI: 9.9, NE) for 1L and 2L+ patients, respectively, and NE for cough and chest pain.
Conclusions:
Capmatinib was associated with clinically meaningful improvements in cough and preserved QoL, further supporting its use in patients with METex14-mutated aNSCLC.
Trial Registration:
ClinicalTrials.gov registry number: NCT02414139.
Insights
Capmatinib improved cough and maintained quality of life in patients with MET exon 14-mutated advanced non-small cell lung cancer, demonstrating its therapeutic potential.
Area of Science:
- Oncology
- Medical Science
- Pharmacology
Background:
- Capmatinib is a MET inhibitor investigated for advanced non-small cell lung cancer (aNSCLC) with MET exon 14 (METex14) mutations.
- The GEOMETRY mono-1 study demonstrated capmatinib's antitumour activity and manageable side effects in this patient population.
Purpose of the Study:
- To report patient-reported outcomes (PROs) from the GEOMETRY mono-1 study of capmatinib in patients with METex14-mutated aNSCLC.
- To assess the impact of capmatinib on quality of life and symptom burden.
Main Methods:
- Patients with aNSCLC and METex14-skipping mutations received capmatinib (400 mg twice daily).
- PROs were collected at baseline and every six weeks using EORTC QLQ-C30, QLQ-LC13, and EQ-5D-5L questionnaires.
- Compliance rates for PROs remained above 70% throughout the study.
Main Results:
- Capmatinib treatment led to early and sustained improvements in cough.
- Quality of life (QoL) and visual analogue scale (VAS) scores improved by week 7 and were generally maintained.
- Median time to definitive deterioration (TTDD) for global health status/QoL was 16.6 months (1L) and 12.4 months (2L+).
- Median TTDD for dyspnoea was over 19 months for both treatment groups.
Conclusions:
- Capmatinib demonstrated clinically meaningful improvements in cough and preserved QoL in patients with METex14-mutated aNSCLC.
- These PROs support the efficacy and tolerability of capmatinib in this specific patient group.
